Pharmafile Logo
Pharmafocus logo
Advanced Search

tecentriq

Showing 15 posts of 48 posts found.

Roche’s Tecentriq scores CHMP recommendation in PD-L1+ metastatic triple-negative breast cancer

July 2, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Roche, breast cancer, pharma, tecentriq

Roche’s immunotherapy Tecentriq (atezolizumab) has been recommended by the EMA’s Committee for Medicinal Products for Human Use (CHMP) in combination …

News
roche__tree

Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer

April 1, 2019
Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma, tecentriq

Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of …

News

Roche’s Tecentriq chalks up another FDA approval, this time in first-line extensive-stage small cell lung cancer

March 20, 2019
Research and Development, Sales and Marketing FDA, Roche, lung cancer, pharma, tecentriq

Roche has secured another US approval for its immunotherapy Tecentriq (atezolizumab), as the FDA reveals its approval of the drug …

News
rocherooflr

Roche’s first-line Tecentriq combo scores accelerated FDA review

December 5, 2018
Research and Development ASH 2018, Cancer, Roche, lung cancer, pharma, tecentriq

Roche’s immunotherapy Tecentriq has secured Priority Review from the FDA, the company has announced, in combination with carboplatin and etoposide …

News
roche_dark_0

Roche withdraws Tecentriq combo application in first-line renal cell carcinoma

November 19, 2018
Sales and Marketing Cancer, Roche, avastin, pharma, renal cell carcinoma, tecentriq

The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with …

News
roche_dark_0

Roche’s Tecentriq+chemo boosts survival in first-line non-small cell lung cancer

October 22, 2018
Research and Development, Sales and Marketing Cancer, Roche, lung cancer NSCLC, pharma, tecentriq

Roche joined other major players like Bristol-Myers Squibb in revealing strong data on their cancer immunotherapies at the European Society …

News

Roche’s Tecentriq+chemo combo shows first-line benefit in small cell lung cancer

September 26, 2018
Research and Development Cancer, Combo, Roche, chemotherapy, lung cancer, pharma, tecentriq

Roche has unveiled new Phase 3 data for its cancer immunotherapy Tecentriq (atezolizumab) in combination with carboplatin and etoposide chemotherapy …

News
roche__tree

Roche’s Tecentriq combo extends life in untreated lung cancer

June 25, 2018
Research and Development, Sales and Marketing Cancer, Roche, lung cancer, pharma, tecentriq

Roche has unveiled new data on the efficacy of Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the …

News
roche

Roche’s breast, lung cancer offerings fail to impress at ASCO

June 4, 2018
Research and Development, Sales and Marketing ASCO, Cancer, Roche, breast cancer, lung cancer, pharma, taselisib, tecentriq

Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data …

News

Roche’s Tecentriq/chemo combo smashes both co-primary endpoints at Phase 3

May 29, 2018
Manufacturing and Production, Research and Development Cancer, NSCLC, Roche, immunotherapy, lung cancer, pharma, tecentriq

Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the …

News
jj

J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex

May 29, 2018
Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq

Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …

News
roche_close

Roche gets NICE approval for advanced bladder cancer

May 17, 2018
Sales and Marketing Roche, biotech, drugs, pharma, pharmaceutical, tecentriq

Though trial results for Tecentriq (atezolizumab) may not necessarily be going Roche’s way, after a combination treatment failure, the treatment …

News
roche

Roche’s Tecentriq/Cotellic combo therapy fails to impress in colorectal cancer

May 11, 2018
Medical Communications, Research and Development Cancer, Cotellic, Roche, pharma, tecentriq

Roche has been rocked by a Phase 3 weak showing from its combination Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people …

News
roche__tree

Roche’s immunotherapy lucky streak ends with deaths in trial

April 13, 2018
Medical Communications, Research and Development Exelixis, Roche, biotech, drugs, pharma, pharmaceutical, tecentriq

Roche’s Tecentriq had begun to show signs of reviving its hopes in the competitive PD-1/L1 market, succeeding in two Phase …

News
roche_glass_building

Tecentriq third time lucky after NICE nod in lung cancer

April 9, 2018
Sales and Marketing NICE, Roche, biotech, drugs, lung cancer, pharma, pharmaceutical, tecentriq

After having been knocked by twice by NICE, Roche has finally received a recommendation for Tecentriq’s second-line use in non-small …

News

Latest content

GSK’s Jemperli approved in EU as treatment for endometrial cancer

December 11, 2023

Daiichi Sankyo shares results for Ezharmia as lymphoma treatment

December 11, 2023

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023